Insmed (INSM) Reports Q2 Loss of $0.72/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
August 3, 2017 7:31 AM EDTOn Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month  Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in the Second Half of 2017 U.S. Food and Drug Administration (FDA) Provides Established Name for Lead Development Program ALIS (amikacin liposome inhalation suspension)
BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) --  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet... More
